GlassScriptPhysician profile
Sergio M Rodriguez
NPI 1013941848
$1,576.37
in general payments reported to CMS, 2019-2025
22 companies · $162 in 2025
The $162 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.20 · 2020: $208 · 2021: $166 · 2022: $230 · 2023: $411 · 2024: $353 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $850 · Education: $76.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $849.54 |
| Education | $76.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $223.32 | 2024-2025 | Rezdiffra, Resmetirom |
| Redhill Biopharma INC. | $146.10 | 2020-2022 | |
| Ironwood Pharmaceuticals, INC | $134.43 | 2020-2023 | Linzess |
| Phathom Pharmaceuticals, INC. | $101.05 | 2024 | Voquezna |
| Janssen Biotech, INC. | $99.93 | 2023 | Stelara |
| Pfizer INC. | $97.70 | 2019-2024 | |
| Abbvie INC. | $93.71 | 2023-2024 | Viberzi, Linzess |
| Celgene Corporation | $76.45 | 2022-2023 | Zeposia |
| Ardelyx, INC. | $76.25 | 2022-2024 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $73.99 | 2020-2023 | Ocaliva |
| Qol Medical, LLC | $66.96 | 2023 | Sucraid |
| Allergan, INC. | $65.97 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.41 | 2022-2025 | Entyvio |
| Boston Scientific Corporation | $58.21 | 2023 | Icefx Cryoablation System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.34 | 2020-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $35.38 | 2020-2023 | Gimoti |
| Novo Nordisk INC | $22.49 | 2021 | |
| Micro-Tech Endoscopy USA, INC. | $22.39 | 2023 | Riteclip |
| Gilead Sciences, INC. | $22.32 | 2021 | |
| Janssen Pharmaceuticals, INC | $21.51 | 2023 | Xarelto |
| Lilly USA, LLC | $21.17 | 2025 | Omvoh |
| Laborie Medical Technologies Corp. | $10.29 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sergio Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.